Jonathan M. Meyer

Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III

Joseph P. McEvoy, Jonathan M. Meyer, Donald Goff et al. · Schizophrenia Research · 2005 · 1.1K citations

Intervention Effectiveness, Metabolic Syndrome, Metabolic Disorder +11

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1

Jonathan M. Meyer, Vicki G. Davis, Donald Goff et al. · Schizophrenia Research · 2008 · 285 citations · Full text

Catie Schizophrenia Trial, Metabolic Syndrome, Psychiatry +9

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

Gail L. Daumit, Donald Goff, Jonathan M. Meyer et al. · Schizophrenia Research · 2008 · 222 citations · Full text

Risk Prediction, Psychiatry, Psychotic Disorder +6

Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study

Jonathan M. Meyer, Joseph P. McEvoy, Vicki G. Davis et al. · Biological Psychiatry · 2009 · 108 citations · Full text

Psychiatry, Psychotic Disorder, Psychotropic Medication +9

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1

Jonathan M. Meyer, Vicki G. Davis, Joseph P. McEvoy et al. · Schizophrenia Research · 2008 · 74 citations · Full text

Antipsychotic Treatment, Psychiatry, Psychotic Disorder +8